10 Best AbCellera Alternatives & Competitors (2026)

Adimab offers yeast-based antibody discovery and optimization services emphasizing high-affinity binders and engineering for pharma partners. It leverages display technologies for rapid affinity maturation across diverse targets. Compared to Abalone Bio, Adimab centers on binding and developability rather than direct functional activity screening at 100M scale. Its yeast platform shares some similarities but does not link survival to GPCR activation or generate activity datasets for AI design of agonists. Abalone Bio's FAST approach provides an edge for activating challenging receptors where Adimab's methods may require extensive secondary assays.

Absci combines AI with synthetic biology for de novo antibody and protein design, screening libraries in high-throughput cellular assays. It targets broad biologics applications including some GPCR-related work. While Absci integrates AI heavily, it relies more on generative models from binding or expression data than Abalone Bio's proprietary functional activity measurements from 100 million antibodies. Abalone Bio's yeast survival linkage directly ties to GPCR modulation, offering stronger specificity for activators. Absci may suit general design needs but trails in scale of real functional GPCR data for side-effect-reduced therapies.

Twist Bioscience provides synthetic DNA libraries and NGS-based antibody discovery tools for custom biologics development. It enables large library construction and sequencing for binder identification across therapeutic areas. In contrast to Abalone Bio's function-first FAST platform measuring activity in parallel for GPCRs, Twist focuses on library diversity and binding workflows without integrated massive functional assays or activity-trained AI. This makes Twist suitable for initial library generation but less competitive for discovering rare activating antibodies where Abalone Bio's datasets unlock new targets.

Genmab develops differentiated antibody therapeutics using proprietary platforms like DuoBody for multispecifics, with a focus on oncology and autoimmune diseases. It has approved products emphasizing effector function and targeting. Unlike Abalone Bio's emphasis on GPCR activation via high-scale functional screening, Genmab prioritizes established antibody formats for inhibition or depletion. Its clinical success highlights specificity advantages but lacks Abalone Bio's yeast-based activity measurement or AI for hard-to-drug activators, positioning it better for validated targets than novel GPCR therapies.

Harbour BioMed specializes in transgenic mouse platforms for fully human antibody discovery, generating leads for immunology and oncology. It supports internal pipelines and partnerships with conventional screening. Compared to Abalone Bio, it does not employ massively parallel functional activity testing or GPCR-specific activation datasets. Harbour's strength lies in in vivo maturation for binders, but Abalone Bio's FAST and AI edge out for designing activators with fewer off-target effects on challenging receptors.

Xencor engineers antibody Fc domains and multispecifics for enhanced function in cancer and autoimmune indications using its XmAb platform. It focuses on modulating immune responses through validated mechanisms. In comparison, Abalone Bio targets upstream GPCR activation with activity-first discovery at unprecedented scale. Xencor's engineering excels post-discovery but does not match Abalone Bio's ability to find rare functional hits via 100M assays or activity-powered AI for new targets.

MorphoSys uses phage display and Ylanthia libraries for antibody discovery, with approved products and partnerships in oncology. It emphasizes high-quality binders and optimization. Relative to Abalone Bio's FAST platform for GPCR activators, MorphoSys relies on display-based binding selection without equivalent functional activity scale or dedicated AI from activity datasets. This suits traditional inhibition-focused programs but offers less for Abalone Bio's niche of activating hard-to-drug targets with specificity.

Sorrento Therapeutics develops antibody and cell therapies using G-MAB library and other platforms for oncology and pain. It includes some GPCR targeting via traditional methods. Unlike Abalone Bio's function-centric 100M antibody screening and ML design, Sorrento prioritizes library diversity for binders. Its broader portfolio may overlap in disease areas but lacks the specialized activity measurement for precise GPCR activation and reduced side effects that defines Abalone Bio.

Agenus focuses on antibody discovery and immuno-oncology with platforms like Retrocyte Display for rapid lead generation. It supports checkpoint and bispecific programs. Compared to Abalone Bio, Agenus centers on immune modulation via binding rather than GPCR functional activation at massive scale. Its display tech enables quick hits but without Abalone Bio's yeast-linked activity assays or proprietary datasets for AI-driven activator design on challenging targets.